Adamo V, Maisano R, Pergolizzi S, Altavilla G, Caristi N, Chiofalo G, Scimone A, Settineri N
Institute of Oncology and Research on Cancer, University of Messina, Italy.
J Chemother. 1997 Feb;9(1):72-6. doi: 10.1179/joc.1997.9.1.72.
The aim of this study was to evaluate three active agents, bleomycin (BLM), epirubicin and carboplatin in a new combination (BECA) in terms of feasibility, activity and toxicity in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. From April 1992 to February 1993 15 pts (12M/3F), median age 53 years, all pretreated (6 surgery + radiotherapy; 3 radiotherapy + chemotherapy; 6 radiotherapy), were treated with BLM 15 mg/m2 days 1-14; epirubicin 30 mg/m2 days 1-14 and carboplatin 300 mg/m2 day 1 every 28 days. In the 14 evaluable pts we observed 1 complete response, CR (7.1%), 4 partial responses, PR (28.6%), 5 stable disease, SD and 4 disease progression, PD with an overall response of 35.7%. The treatment was globally well tolerated, 1 pt with grade 3 leukopenia and 1 pt with grade 3 thrombocytopenia, 1 pt with grade 3 emesis and 1 pt with grade 3 mucositis. At the last follow-up the duration of CR was 34 months, the duration of PRs were respectively 22-10-10-7 months, but the SD ranged from 4 to 6 months. The overall median survival was 8 months (3-36), 14 for responders and 4 for non-responders. This final report seems to confirm the activity and efficacy of the BECA regimen, suitable for outpatient administration with an overall response equal to other more aggressive combinations.
本研究旨在评估博来霉素（BLM）、表柔比星和顺铂这三种活性药物新组合（BECA）对复发性和转移性头颈部鳞状细胞癌患者的可行性、活性和毒性。1992年4月至1993年2月，15例患者（12例男性/3例女性），中位年龄53岁，均接受过预处理（6例手术+放疗；3例放疗+化疗；6例放疗），接受以下治疗：博来霉素15mg/m²，第1 - 14天；表柔比星30mg/m²，第1 - 14天；顺铂300mg/m²，第1天，每28天重复。在14例可评估患者中，我们观察到1例完全缓解（CR，7.1%），4例部分缓解（PR，28.6%），5例疾病稳定（SD），4例疾病进展（PD），总缓解率为35.7%。总体而言，该治疗耐受性良好，1例患者出现3级白细胞减少，1例患者出现3级血小板减少，1例患者出现3级呕吐，1例患者出现3级黏膜炎。在最后一次随访时，CR持续时间为34个月，PR持续时间分别为22 - 10 - 10 - 7个月，但SD持续时间为4至6个月。总中位生存期为8个月（3 - 36个月），缓解者为14个月，未缓解者为4个月。这份最终报告似乎证实了BECA方案的活性和疗效，该方案适合门诊给药，总体缓解率与其他更积极的联合方案相当。
